Search

Displaying results 3071 - 3080 of 10000 in total
  1. Drug

    Diethylamino hydroxybenzoyl hexyl benzoate

    go.drugbank.com/drugs/DB11269
    Approved

    It is used in concentrations up to 10% in sunscreen products, either alone or in combination with other UV absorbers [F107]. … Diethylamino hydroxybenzoyl hexyl benzoate was approved in Europe in 2005, and is also marketed in the U.S., South America, Mexico, Japan and Taiwan.

  2. Drug

    Tegafur-uracil

    go.drugbank.com/drugs/DB09327
    Approved

    Tegafur-uracil is an anti-tumor compound containing tegafur (1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil in a molar ratio of 1:4. … It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd.[A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.

  3. Drug

    Narsoplimab

    go.drugbank.com/drugs/DB16418
    ApprovedInvestigational

    [A241030] Evidence increasingly points to a role for the complement system in TMA. … [A241045, A241050] Approved by the FDA on December 24, 2025, narsoplimab-wuug is indicated for the treatment of hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in adults

    Synonyms: IMMUNOGLOBULIN G4-LAMBDA, ANTI-(HOMO SAPIENS MANNAN-BINDING LECTIN SERINE PROTEASE 2 (MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASE 2, EC=3.4.21.104) HUMAN MONOCLONAL ANTIBODY .GAMMA.4 HEAVY CHAIN
  4. Drug

    Pacritinib

    go.drugbank.com/drugs/DB11697
    ApprovedInvestigational

    has made it a desirable therapeutic target in MF treatment. … Pacritinib is an inhibitor of both wild-type and mutant (V617F) JAK2, as well as FMS-like tyrosine kinase 3 (FLT3), which was granted accelerated approval by the FDA in February 2022 for the treatment

  5. Drug

    DG041

    go.drugbank.com/drugs/DB05027
    Experimental

    DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2. … It block the formation of blood clots mediated through inflammation in atherosclerotic plaques but without increasing bleeding risk.

  6. Drug

    Metolazone

    go.drugbank.com/drugs/DB00524
    ApprovedInvestigational

    A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss.

  7. Drug

    Bentonite

    go.drugbank.com/drugs/DB11306
    ApprovedWithdrawn

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    N,N'-diphenyl-1,4-phenylenediamine

    go.drugbank.com/drugs/DB14192
    Approved

    Categories: Compounds used in a research, industrial, or household settingSynonyms: N,N'-diphenyl-1,4-phenylenediamine
  9. Drug

    Cromoglicic acid

    go.drugbank.com/drugs/DB01003
    ApprovedInvestigational

    It is used in the prophylactic treatment of both allergic and exercise-induced asthma, but does not affect an established asthmatic attack. … A chromone complex that acts by inhibiting the release of chemical mediators from sensitized mast cells.

    Mixtures: OSMOCROM-N ®Products: INTAL N, Gen-cromolyn Nasal Spray
  10. Drug

    Human botulinum neurotoxin A/B immune globulin

    go.drugbank.com/drugs/DB14115
    Approved

    Infant botulism is a rare infectious disease occurring in infants in which _Clostridium botulinum_ colonize the large intestine and being to produce botulinum neurotoxin directly in the gut. … [L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in 2003[L39814] and has since been used to treat more than 2100 cases of infant botulism.